Product Description
AOBO-001 oral capsule is developed from traditional Chinese herbal medicine for the treatment of UI. (Sourced from: https://www.sec.gov/Archives/edgar/data/1090514/000119312509053848/dex993.htm)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: American Oriental Bioengineering
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Enuresis|Overactive Bladder|Urinary Incontinence, Urge
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01294982 | P2 |
Completed |
Enuresis|Overactive Bladder|Urinary Incontinence, Urge |
2011-11-01 |